- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00370214
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Pulmonary arterial hypertension (PAH) is a chronic, progressive, and often fatal disease characterized by severe constriction of the blood vessels in the lungs. Over the past decade, significant strides have been made in the medical management and understanding of PAH. However, much remains to be learned about the clinical course of both idiopathic PAH and associated PAH, including clinical presentation, pace of progression, key parameters to monitor, impact of treatment, and prognosticators of outcome. As the unique body of knowledge generated by the REVEAL Registry grows, it is hoped that new understandings, insights, and treatments will emerge that will improve the lives of patients with PAH.
The REVEAL Registry will provide investigators with descriptive data regarding the clinical course and treatment outcomes in patients with WHO Group I PAH. Data derived from the study may offer important tools for assessing current management practices of treating investigators, as well as changes over time. Additionally, the relationship of patient- and disease-specific parameters to patient outcomes may be able to be assessed through analysis of data from this study.
The specific objectives of the REVEAL Registry™ are to:
- Characterize the demographics and clinical course of PAH patients
- Evaluate and compare patient outcomes
- Identify clinical predictors of short-term and long-term clinical outcomes
- Assess the relationship between PAH medications and patient outcomes
- Report temporal trends in treatments and outcomes for newly diagnosed patients
- Collect timely and relevant data for the evolving research needs of the PAH community
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85724
- University of Arizona Medical Center
-
-
California
-
La Jolla, California, Vereinigte Staaten, 92037
- University of California, San Diego
-
Los Angeles, California, Vereinigte Staaten, 90095
- UCLA Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90073
- UCLA / VA Medical Center
-
San Francisco, California, Vereinigte Staaten, 94143
- Univeristy of California, San Francisco - Division of Cardiology and Pediatric ICU
-
Stanford, California, Vereinigte Staaten, 94305
- Stanford University Medical Center
-
Torrance, California, Vereinigte Staaten, 90502
- UCLA School of Medicine: Harbor-UCLA
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- The Children's Hospital
-
Denver, Colorado, Vereinigte Staaten, 80262
- University of Colorado Health Sciences Center
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- University of Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Mayo Clinic
-
Sarasota, Florida, Vereinigte Staaten, 34233
- Suncoast Lung Center
-
-
Georgia
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Medical College of Georgia
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Hospitals
-
Naperville, Illinois, Vereinigte Staaten, 60566
- Midwest Heart Foundation
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa Health Care
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Kentucky Pulmonary Associates
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21205
- Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Boston University School Of Medicine
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Tufts-New England Medical Center
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University
-
Grand Rapids, Michigan, Vereinigte Staaten, 49506
- Spectrum Health Hospitals
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota Medical Center
-
Rochester, Minnesota, Vereinigte Staaten, 55095
- Mayo Clinic
-
-
Missouri
-
St. Louis, Missouri, Vereinigte Staaten, 63021
- Washington University School of Medicine
-
-
New York
-
Manhasset, New York, Vereinigte Staaten, 11030
- North Shore University Hospital
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University
-
New York, New York, Vereinigte Staaten, 10003
- Beth Israel Medical Center
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospital of Cleveland
-
Cleveland, Ohio, Vereinigte Staaten, 44022
- Cleveland Clinic Foundation
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Children's Hospital
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97210
- Legacy Pulmonary Hypertension Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Temple Lung Center
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Penn Presbyterian Medial Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, Vereinigte Staaten, 37212
- Vanderbilt Children's Hospital
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Baylor College of Medicine
-
Houston, Texas, Vereinigte Staaten, 77030
- Texas Children's Hospital
-
San Antonio, Texas, Vereinigte Staaten, 78229
- University Texas Health Science Center
-
-
Utah
-
Murray, Utah, Vereinigte Staaten, 84107
- Intermountain Medical Center
-
-
Virginia
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Inova Heart and Vascular Institute
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Seattle Children's
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Aurora St. Luke's Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Newly diagnosed or previously diagnosed patients with WHO Group I PAH.
- Documentation of the following hemodynamic parameters by right heart catheterization, performed at any time prior to study enrollment:
- Mean pulmonary arterial pressure (mPAP) >25 mm Hg at rest or mPAP > 30 mm Hg with exercise contemporaneous with a pulmonary wedge pressure ≤ 18 mm Hg
- Pulmonary wedge pressure ≤ 18 mm Hg
- Pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 (i.e., ≥ 3.0 Wood units)
Exclusion Criteria:
- Patients who meet the criteria for inclusion into WHO Groups II, III, IV or V
- Have not had documentation of hemodynamic criteria for PAH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PAH.
- Do not meet the required hemodynamic criteria for entry into the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Überleben
Zeitfenster: 5 Jahre
|
5 Jahre
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
clinical predictors, precise outcome definitions
Zeitfenster: 5 years
|
5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Michael D. McGoon, M.D., Mayo Clinic - Rochester, Minnesota
- Studienleiter: David B. Badesch, M.D., University of Colorado, Denver
- Studienleiter: Robyn J. Barst, M.D., Columbia University
- Studienleiter: Raymond Benza, M.D., University of Alabama at Birmingham
- Studienleiter: Gregory Elliott, M.D., LDS Hospital
- Studienleiter: Harrison Farber, M.D., Boston Medical Center
- Studienleiter: Adaani Frost, M.D., Baylor College of Medicine
- Studienleiter: Abby Krichman, RRT, Duke University Pulmonary Vascular Disease Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.
- Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, Elliott CG, Farber HW. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021 Jan;159(1):337-346. doi: 10.1016/j.chest.2020.08.2069. Epub 2020 Sep 1.
- Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.
- Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015 Dec 22;132(25):2403-11. doi: 10.1161/CIRCULATIONAHA.115.018435. Epub 2015 Oct 28.
- Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300.
- Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014 Dec;146(6):1494-1504. doi: 10.1378/chest.13-3014.
- Burger CD, Long PK, Shah MR, McGoon MD, Miller DP, Romero AJ, Benton WW, Safford RE. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014 Nov;146(5):1263-1273. doi: 10.1378/chest.14-0193.
- Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013 Nov;144(5):1521-1529. doi: 10.1378/chest.12-3023.
- Bersohn MM, Turner MP, Traiger GL, Frost AE, Shapiro S. Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension. Chest. 2013 Sep;144(3):959-965. doi: 10.1378/chest.12-2572.
- Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013 Jul;144(1):160-168. doi: 10.1378/chest.12-2417.
- Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013 Jul;144(1):169-176. doi: 10.1378/chest.11-3241.
- Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R). Mayo Clin Proc. 2012 Sep;87(9):825-34. doi: 10.1016/j.mayocp.2012.05.014. Epub 2012 Aug 9.
- Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013 Jan;143(1):185-195. doi: 10.1378/chest.11-1387.
- Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug;142(2):448-456. doi: 10.1378/chest.11-1460.
- Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012 Jan 3;125(1):113-22. doi: 10.1161/CIRCULATIONAHA.111.026591. Epub 2011 Nov 15.
- Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012 Apr;141(4):906-915. doi: 10.1378/chest.11-0160. Epub 2011 Jul 21.
- Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012 Feb;141(2):363-373. doi: 10.1378/chest.10-3114. Epub 2011 Jul 14.
- Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012 Feb;141(2):354-362. doi: 10.1378/chest.11-0676. Epub 2011 Jun 16.
- Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011 Jul;140(1):19-26. doi: 10.1378/chest.10-1166. Epub 2011 Mar 10.
- Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc. 2011 Feb;86(2):105-12. doi: 10.4065/mcp.2010.0394.
- Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13;122(2):164-72. doi: 10.1161/CIRCULATIONAHA.109.898122. Epub 2010 Jun 28.
- Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan;139(1):128-37. doi: 10.1378/chest.10-0075. Epub 2010 Jun 17. Erratum In: Chest. 2011 Oct;140(4):1106.
- Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, Miller DP, Nicolls MR, Zamanian RT. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010 Dec;138(6):1383-94. doi: 10.1378/chest.10-0260. Epub 2010 May 27.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CR001
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Pulmonale Hypertonie
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich